Prostate Cancer Screening Cheboygan MI

Prostate cancer screening consists of diagnostic tests that can assist with early detection of prostate cancer. Screening may involve a digital rectal exam, prostate-sspecific antigen (PSA) blood test, or a transrectal ultrasound. See below to learn more and to gain access to qualified oncologists in Cheboygan, MI who provide prostate cancer screening.

Sandra Lee Mantz, MD
512-882-4101
5885 N Conway Rd
Alanson, MI
Paul Adams, MD
810-762-8226
302 Kensington Ave Ste 1131
Flint, MI
Kenneth Alan Schwartz
(517) 975-9500
401 W Greenlawn Ave
Lansing, MI
Sandeep Garg, MD
44038 Woodward Ave Ste 101
Bloomfield Hills, MI
Mark M Zalupski
(734) 936-6000
1500 East Medical Center Dr
Ann Arbor, MI
Andrew Thomas Turrisi, MD
313-966-2274
3900 John R St
Detroit, MI
Joyce Renick Fahrner, MD
810-762-8400
302 Kensington Ave
Flint, MI
Judith L Ramsdell
(231) 935-0777
5041 N Royal Dr
Traverse City, MI
Leopoldo Eisenberg, MD
248-305-7029
42450 W 12 Mile Rd Ste 100
Novi, MI
Ammar Sukari, MD
586 778 4950
22811 Greater Mac Ave. Suite 205
Saint Clair Shores, MI
Data Provided by:
  

All about the PSA Test

The PSA (Prostate-Specific Antigen) test is one of two primary screening tools for prostate cancer. This simple blood test measures the level of PSA, a protein produced in the prostate, present in a man's body. Men typically have an initial PSA screening at 50, or earlier if there's a family history of prostate cancer.

Physicians measure PSA in nanograms per milliliter. An elevated PSA doesn't diagnose cancer and doesn't mean a man has prostate cancer; it just suggests further evaluation. Other medical conditions can also raise PSA levels. A PSA test and additional diagnostic tools help detect small tumors, however, experts say it does not necessarily reduce a man's chance of dying of prostate cancer.

An increase in PSA is the strongest single predictor of prostate cancer risk, and a high PSA score followed by a lower PSA score is not uncommon, even in men who do have cancer. However, PSA progression does predict poor overall survival rates in men with mestacized prostate cancer (meaning it has spread beyond the prostate). The PSA test is actually a better predictor of prostate cancer risk in African-American men with family histories compared to European- American men.

There is controversy over the value of PSA screenings. This spring, researchers released the results of a large-scale study that began in 1992 to evaluate whether or not the PSA test benefited men. In the subsequent media coverage of the results, the news varied widely depending on who was doing the reporting...

Click here to read more from Quality Health